Survey of Ophthalmology
Volume 47, Issue 5 , Pages 491-499 , September 2002

A Sticky Situation

References 

  1. Alarcon-Segovia D, Sanchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol. 1989;16:482–488
  2. Ameri A, Bousser MG. Cerebral venous thrombosis. Neurol Clin. 1992;10:87–111
  3. Bertina RM, Rosendaal FR. Venous thrombosis—the interaction of genes and environment. N Engl J Med. 1998;338:1840–1841
  4. Bianchi D, Maeder P, Bogousslavsky J, et al.  Diagnosis of cerebral venous thrombosis with routine magnetic resonance (an update). Eur Neurol. 1998;40:179–190
  5. Biousse V, Ameri A, Bousser MG. Isolated intracranial hypertension as the only sign of cerebral venous thrombosis. Neurology. 1999;53:1537–1542
  6. Biousse V, Bousser MG. Cerebral venous thrombosis. The Neurologist. 1999;5:326–349
  7. Biousse V, Conard J, Brouzes C, et al.  Frequency of the 20210 G→A mutation in the 3-untranslated region of the prothrombin gene in 35 cases of cerebral venous thrombosis. Stroke. 1998;29:1398–1400
  8. Biousse V, Piette JC. Genetic aspects of the primary antiphospholipid syndrome. Nouv Rev Fr Hematol. 1995;37(Suppl):S65–S67
  9. Bousser MG. Cerebral venous thrombosis (nothing, heparin, or local thrombolysis?). Stroke. 1999;30:481–483
  10. Bousser MG, Russell RR. Cerebral Venous Thrombosis. London: Saunders; 1997;
  11. Brucker AB, Vollert-Rogenhofer H, Wagner M, et al.  Heparin treatment in acute cerebral sinus venous thrombosis (a retrospective clinical and MR analysis of 42 cases). Cerebrovasc Dis. 1998;8:331–337
  12. Carhuapoma JR, Mitsias P, Levine SR. Cerebral venous thrombosis and anticardiolipin antibodies. Stroke. 1997;28:2363–2369
  13. Corbett JJ, Thompson HS. The rational management of idiopathic intracranial hypertension. Arch Neurol. 1989;46:1049–1051
  14. de Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke. 1999;30:484–488
  15. de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP: Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. The Cerebral Venous Sinus Thrombosis Study Group. BMJ 316:589–92, 1998
  16. de Bruijn SF, Stam J, Vandenbroucke JP. Increased risk of cerebral venous sinus thrombosis with third-generation oral contraceptive. Lancet. 1998;351:1404
  17. Deschiens MA, Conard J, Horellou MH, et al.  Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke. 1996;27:1724–1730
  18. deVeber G, Chan A, Monagle P, et al.  Anticoagulation therapy in pediatric patients with sinovenous thrombosis (a cohort study). Arch Neurol. 1998;55:1533–1537
  19. Diaz JM, Schiffman JS, Urban ES, Maccario M. Superior sagittal sinus thrombosis and pulmonary embolism (a syndrome rediscovered). Acta Neurol Scand. 1992;86:390–396
  20. Easton JD, Bousser MG, Stam J. Treatment of cerebral venous thrombosis. Cerebrovasc Dis. 1993;3:329–332
  21. Einhaupl KM, Villringer A, Meister W, et al.  Heparin treatment in sinus venous thrombosis. Lancet. 1991;338:597–600
  22. Einhaüpl KM, Masuhr F. Cerebral venous and sinus thrombosis (an update). Eur J Neurol. 1994;1:109–126
  23. Isensee C, Reul J, Thron A. Magnetic resonance imaging of thrombosed dural sinuses. Stroke. 1994;25:29–34
  24. Kalbag RM, Woolf AL. Cerebral Venous Thrombosis. Vol 1. London: Oxford University Press; 1967;
  25. Khamashta MA, Cuadrado MJ, Mujic F, et al.  The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332:993–997
  26. Lane DA, Mannucci PM, Bauer KA, et al.  Inherited thrombophilia (part 2). Thromb Haemost. 1996;76:824–834
  27. Lane DA, Mannucci PM, Bauer KA, et al.  Inherited thrombophilia (part 1). Thromb Haemost. 1996;76:651–662
  28. Levine SR, Kieran S, Puzio K, et al.  Cerebral venous thrombosis with lupus anticoagulants. Report of two cases. Stroke. 1987;18:801–804
  29. Mas JL, Meder JF, Meary E. Dural sinus thrombosis (long-term follow-up by magnetic resonance imaging). Cerebrovasc Dis. 1992;2:137–144
  30. Mas JL, Meder JF, Meary E, Bousser MG. Magnetic resonance imaging in lateral sinus hypoplasia and thrombosis. Stroke. 1990;21:1350–1356
  31. Preter M, Tzourio C, Ameri A, Bousser MG. Long-term prognosis in cerebral venous thrombosis. Follow-up of. 1996;77(patients. Stroke 27):243–246
  32. Provenzale JM, Loganbill HA. Dural sinus thrombosis and venous infarction associated with antiphospholipid antibodies (MR findings). J Comput Assist Tomogr. 1994;18:719–723
  33. Purvin VA, Trobe JD, Kosmorsky G. Neuro-ophthalmic features of cerebral venous obstruction. Arch Neurol. 1995;52:880–885
  34. Radhakrishnan K, Ahlskog JE, Garrity JA, Kurland LT. Idiopathic intracranial hypertension. Mayo Clin Proc. 1994;69:169–180
  35. Southwick FS, Richardson EP, Swartz MN. Septic thrombosis of the dural venous sinuses. Medicine (Baltimore). 1986;65:82–106
  36. Tehindrazanarivelo A, Evrard S, Schaison M. Prospective study of cerebral sinus venous thrombosis in patients presenting with benign intracranial hypertension. Cerebrovasc Dis. 1992;2:22–27
  37. Vidailhet M, Piette JC, Wechsler B, et al.  Cerebral venous thrombosis in systemic lupus erythematosus. Stroke. 1990;21:1226–1231
  38. Wingerchuk DM, Wijdicks EF, Fulgham JR. Cerebral venous thrombosis complicated by hemorrhagic infarction (factors affecting the initiation and safety of anticoagulation). Cerebrovasc Dis. 1998;8:25–30

☆ Comments by Valerie Biousse, MD, and Nancy J. Newman, MD

☆☆ (In keeping with the format of a clinical pathological conference, the abstract and key words appear at the end of the article.)

★ The authors reported no propietary or commercial interest in any product mentioned or concept discussed in this article. This study was supported in part by a departmental grant (department of Ophthalmology) from Research to Prevent Blindness, Inc, New York, New York, and by core grant P30-EY06360 (Department of Ophthalmology) from the National Institutes of Health, Bethesda, Maryland. Dr. Newman is a recipient of the Research to Prevent Blindness Lew R. Wasserman Merit Award.

PII: S0039-6257(02)00339-9

Survey of Ophthalmology
Volume 47, Issue 5 , Pages 491-499 , September 2002

Article Tools

* Image Usage & Resolution